Logo

Progenity: Brian Kotzin

Aug 07, 2019

Progenity has appointed Brian Kotzin to its board of directors. Kotzin is currently on the board of directors for Rigel, and serves as a principal fellow and senior vice president for Nektar Therapeutics. His previous roles include vice president of global clinical development and head of the inflammation therapeutic area, and vice president and head of medical sciences at Amgen. Prior to entering the life sciences industry, he held several professorships at the University of Colorado Health Sciences Center, where his research focused on immunopathogenesis of disease.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.